Cesca Therapeutics and Fortis Healthcare Announce Master Collaboration Agreement

Cesca Therapeutics and Fortis Healthcare Announce Master Collaboration

Cesca Therapeutics Expands Scope of Services as Exclusive Provider of
Regenerative Medicine to the Largest Private Hospital in Asia

RANCHO CORDOVA, Calif. and GURGAON, India, Aug. 5, 2014 (GLOBE NEWSWIRE) --
Cesca Therapeutics, an autologous cell-based regenerative medicine company,
and Fortis Healthcare Limited, India's fastest growing hospital network,
announced a master collaboration agreement that extends their important
existing relationship. The agreement affirms Cesca's cellular therapy and cord
blood bank at the Fortis Hospital Memorial Research Institute (FMRI) in
Gurgaon, renews the cord blood banking collaboration and launches the stem
cell therapy services for hematological diseases across the Fortis network.
The scope of services now provide for specific regenerative medicine programs
including: cord blood banking services, point of care autologous cell therapy
product and services, hematopoietic stem cell therapy services (i.e. both
autologous and allogeneic bone marrow transplant) and oncological cellular
therapy services.

Fortis Healthcare

Fortis Healthcare and Cesca Therapeutics will continue to leverage Fortis'
hospital network and respective areas of clinical expertise to launch
world-class matched and unmatched bone marrow transplants and create more
awareness around the benefits of stem cell therapy across India.

"We are honored to continue this important long standing relationship with
Fortis and to add additional components into the master collaboration
agreement. The collaboration will allow us to continue to carry out advanced
clinical research and provide world-class clinical facilities and equipment to
physicians and patients in India," said Matthew Plavan, Chief Executive
Officer of Cesca Therapeutics.

"The collaboration with Fortis, the largest private hospital in Asia, will
allow the partnership to continue to advance cellular therapy in private
healthcare in India to unmatched levels," said Kenneth Harris, President of
Cesca Therapeutics. "In addition, the collaboration enhances advancements in
regenerative therapies for pediatric and adult hematological diseases in the
Fortis-TotipotentRX Center for Cellular Medicine within the Fortis Memorial
Research Institute," he continued.

"We believe that cell therapies are critical to the future success of
healthcare services world-wide. An example is Cesca's proven ability to
translate stem cell science into advanced therapies in combination with our
world renowned physician's clinical expertise all leading to the most advanced
pediatric bone marrow transplant cell therapy program in India," said Aditya
Vij, CEO of Fortis Healthcare. "We look forward to continuing this important
partnership with a leading regenerative medicine company," continued Vij.

About Cesca Therapeutics Inc.

Cesca Therapeutics Inc. (www.cescatherapeutics.com) is engaged in the
research, development, and commercialization of autologous cell-based
therapeutics for use in regenerative medicine. We are a leader in developing
and manufacturing automated blood and bone marrow processing systems that
enable the separation, processing and preservation of cell and tissue therapy
products.These include:

  *SurgWerks™ Platform, proprietary stem cell therapy point-of-care kit
    systems for treating vascular and orthopedic indications that integrate
    the following indication specific systems:

    *Cell harvesting
    *Cell processing and selection
    *Cell diagnostics
    *Cell delivery

  *CellWerks^TM Platform, a proprietary stem cell laboratory technology for
    processing target cells used in the treatments of oncological and
    hematological disorders.
  *AXP^® AutoXpress^® Platform (AXP), a proprietary family of automated
    devices that includes the AXP and the MXP^® MarrowXpress^® and companion
    sterile blood processing disposables for harvesting stem cells in closed
    systems. The AXP device is used for the processing of cord blood.
  *The MarrowXpress Platform (MXP), a derivative product of the AXP and its
    accompanying disposable bag set, isolates and concentrates stem cells from
    bone marrow. Self-powered and microprocessor-controlled, the MXP contains
    flow control optical sensors that volume-reduces blood from bone marrow to
    a user defined volume in 30 minutes, while retaining over 90% of the MNCs.
  *The Res-Q™ 60 (Res-Q), a point-of-care system designed for the preparation
    of cell concentrates, including stem cells, from bone marrow aspirates and
    whole blood for platelet rich plasma (PRP).
  *The BioArchive^® System, an automated cryogenic device, used by cord blood
    stem cell banks in more than 30 countries for cryopreserving and archiving
    cord blood stem cell units for transplant.

About Fortis Healthcare Limited

Fortis Healthcare Limited is a leading integrated healthcare delivery service
provider in India. The healthcare verticals of the company primarily comprise
hospitals, diagnostics and day care specialty facilities. Currently, the
company operates its healthcare delivery services in India, Singapore, Dubai,
Mauritius and Sri Lanka with 66 healthcare facilities (including projects
under development), over 10,000 potential beds and approx. 280 diagnostic
centres. In a globalstudy of the 30 most technologically advanced hospitals
in the world, its flagship, the Fortis Memorial Research Institute' (FMRI),
was ranked No.2, by 'topmastersinhealthcare.com, and placed ahead of many
other outstanding medical institutions in the world.

Forward Looking Statement

This press release contains forward-looking statements. Such forward-looking
statements include but are not limited to that Cesca Therapeutics Inc. will be
able to close it proposed offering of Units. These statements and Cesca
Therapeutics' business involve risks and uncertainties that could cause actual
outcomes to differ materially from those contemplated by the forward-looking
statements. A more complete description of risks that could cause actual
events to differ from the outcomes predicted by Cesca Therapeutics'
forward-looking statements is set forth under the caption "Risk Factors" in
Cesca Therapeutics annual report on Form 10-K and other reports it files with
the Securities and Exchange Commission from time to time, and you should
consider each of those factors when evaluating the forward-looking statements.

CONTACT: Cesca Therapeutics Inc.
         Website: http://www.cescatherapeutics.com
         Investor Relations
         +1-916-858-5107, or

         Fortis Healthcare Limited
         Website: http://www.fortishealthcare.com
         Nibha Vyas
         M: +91 9811065557

Cesca Therapeutics Inc. logo
Press spacebar to pause and continue. Press esc to stop.